15.31
-0.14(-0.91%)
Currency In USD
Address
1616 Eastlake Avenue East
Seattle, WA 98102
United States of America
Phone
206 737 0085
Website
Sector
Healthcare
Industry
Biotechnology
Employees
60
First IPO Date
July 29, 2021
| Name | Title | Pay | Year Born |
| Mr. Adam K. Simpson | President, Chief Executive Officer, Co-Founder & Director | 855,950 | 1976 |
| Ms. Elizabeth Bekiroglu | General Counsel & Corporate Secretary | 230,737 | 1970 |
| Mr. Thomas Joseph Russo C.F.A. | Chief Financial Officer | 525,267 | 1972 |
| Dr. Cassia Cearley Ph.D. | Treasurer & Chief Business Officer | 632,150 | 1983 |
| Mr. Niranjan Kanesa-thasan M.D. | Chief Medical Officer | 641,550 | 1961 |
| Dr. Ami Shah Brown MPH, Ph.D. | Senior Vice President of Regulatory Affairs | 0 | N/A |
| Dr. David Baker M.D., Ph.D. | Co-founder & Member of Scientific Advisory Board | 0 | N/A |
| Mr. Neil King Ph.D. | Chair of Scientific Advisory Board & Co-Founder | 0 | N/A |
| Ms. Jennifer Raymond | Senior Vice President of Technical Operations | 0 | N/A |
| Ms. Lori Stewart | Senior Vice President of People & Culture | 0 | N/A |
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in Seattle, Washington.